BridgeBio Pharma (BBIO) News Today $36.94 -1.28 (-3.35%) Closing price 04:00 PM EasternExtended Trading$36.70 -0.24 (-0.66%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Cantor Fitzgerald Has Positive View of BBIO FY2025 EarningsBridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) - Stock analysts at Cantor Fitzgerald upped their FY2025 earnings per share (EPS) estimates for BridgeBio Pharma in a report issued on Wednesday, April 30th. Cantor Fitzgerald analyst J. Schimmer now expects that the company will earn ($3.93) perMay 4 at 8:31 AM | marketbeat.comCantor Fitzgerald Issues Positive Estimate for BBIO EarningsMay 4 at 2:11 AM | americanbankingnews.comThe Manufacturers Life Insurance Company Boosts Stock Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO)The Manufacturers Life Insurance Company increased its position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 23.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,885,794 shares of the company's stock afMay 3 at 5:43 AM | marketbeat.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Bought by Price T Rowe Associates Inc. MDPrice T Rowe Associates Inc. MD grew its position in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 22.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 991,238 shares of the compMay 3 at 4:28 AM | marketbeat.comBridgeBio Pharma (NASDAQ:BBIO) Price Target Raised to $72.00May 3 at 2:45 AM | americanbankingnews.comPiper Sandler Issues Positive Forecast for BridgeBio Pharma (NASDAQ:BBIO) Stock PriceMay 3 at 2:45 AM | americanbankingnews.comBridgeBio Pharma (NASDAQ:BBIO) Sets New 52-Week High on Earnings BeatBridgeBio Pharma (NASDAQ:BBIO) Reaches New 12-Month High After Strong EarningsMay 2, 2025 | marketbeat.comUBS Group Issues Positive Forecast for BridgeBio Pharma (NASDAQ:BBIO) Stock PriceUBS Group increased their target price on shares of BridgeBio Pharma from $65.00 to $72.00 and gave the stock a "buy" rating in a research note on Wednesday.May 2, 2025 | marketbeat.comScotiabank Raises BridgeBio Pharma (NASDAQ:BBIO) Price Target to $55.00May 2, 2025 | americanbankingnews.comBridgeBio Pharma (NASDAQ:BBIO) Reaches New 1-Year High After Better-Than-Expected EarningsMay 2, 2025 | americanbankingnews.comBridgeBio Pharma (NASDAQ:BBIO) Releases Quarterly Earnings Results, Beats Estimates By $0.02 EPSBridgeBio Pharma (NASDAQ:BBIO - Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($0.88) EPS for the quarter, beating the consensus estimate of ($0.90) by $0.02.May 1, 2025 | marketbeat.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Holdings Reduced by Emerald Mutual Fund Advisers TrustEmerald Mutual Fund Advisers Trust cut its position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 3.5% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 724,872 shares of the company's stock after selling 26,483 shares durinMay 1, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Acquires New Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Adage Capital Partners GP L.L.C. acquired a new stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The fund acquired 270,000 shares of the company's stock, valued at approximately $7,409,000. Adage Capital Partners GP L.May 1, 2025 | marketbeat.comTower Research Capital LLC TRC Increases Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Tower Research Capital LLC TRC lifted its holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 889.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 20,778 shares of the companyMay 1, 2025 | marketbeat.comWhy BridgeBio Pharma, Inc. (BBIO) Surged on WednesdayMay 1, 2025 | msn.comBridgeBio Pharma, Inc.: BridgeBio Reports First Quarter 2025 Financial Results and Business UpdatesApril 30, 2025 | finanznachrichten.deBridgeBio Pharma (NASDAQ:BBIO) Trading Down 4.2% - What's Next?BridgeBio Pharma (NASDAQ:BBIO) Stock Price Down 4.2% - What's Next?April 30, 2025 | marketbeat.comStock Traders Purchase Large Volume of BridgeBio Pharma Put Options (NASDAQ:BBIO)BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) was the recipient of some unusual options trading on Monday. Stock investors bought 5,930 put options on the stock. This represents an increase of approximately 67% compared to the average daily volume of 3,542 put options.April 30, 2025 | marketbeat.comSusquehanna Fundamental Investments LLC Makes New $6.53 Million Investment in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Susquehanna Fundamental Investments LLC acquired a new stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 237,995 shares of the compaApril 30, 2025 | marketbeat.comBridgeBio Pharma Inc (BBIO) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ...April 30, 2025 | finance.yahoo.comBridgeBio Pharma, Inc. (BBIO) Q1 2025 Earnings Call TranscriptApril 29, 2025 | seekingalpha.comBridgeBio Pharma, Inc. 2025 Q1 - Results - Earnings Call PresentationApril 29, 2025 | seekingalpha.comBridgeBio Reports First Quarter 2025 Financial Results and Business UpdatesApril 29, 2025 | globenewswire.comBridgeBio Pharma, Inc. (BBIO): Among Billionaire Andreas Halvorsen’s Stock Picks With Huge Upside PotentialApril 29, 2025 | insidermonkey.comNebula Research & Development LLC Raises Stock Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Nebula Research & Development LLC lifted its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 92.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 36,239 shares of the company's stock after buying anApril 29, 2025 | marketbeat.comTraders Buy Large Volume of BridgeBio Pharma Put Options (NASDAQ:BBIO)April 29, 2025 | americanbankingnews.comA Look Ahead: BridgeBio Pharma's Earnings ForecastApril 29, 2025 | benzinga.comSyon Capital LLC Buys New Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Syon Capital LLC purchased a new position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 13,200 shares of the company's stock, valued atApril 28, 2025 | marketbeat.comBEYONTTRA® (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved by the UK Medicines and Healthcare Products Regulatory Agency to Treat ATTR-CMApril 28, 2025 | globenewswire.comBridgeBio Pharma (BBIO) Expected to Announce Earnings on TuesdayApril 27, 2025 | americanbankingnews.comBridgeBio Pharma (BBIO) Projected to Post Earnings on TuesdayBridgeBio Pharma (NASDAQ:BBIO) will be releasing its Q1 2025 earnings after the market closes on Tuesday, April 29. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-4-29-bridgebio-pharma-inc-stock/)April 26, 2025 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), BridgeBio Pharma (BBIO) and Tenaya Therapeutics (TNYA)April 25, 2025 | markets.businessinsider.comXTX Topco Ltd Purchases New Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)XTX Topco Ltd purchased a new position in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 13,329 shares of the company's stock, valued at aApril 25, 2025 | marketbeat.comBridgeBio Pharma Inc.April 23, 2025 | barrons.comSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of BridgeBio Pharma, Inc. (NASDAQ: BBIO)April 23, 2025 | prnewswire.comBridgeBio: Early Signs Point To Blockbuster RevenuesApril 23, 2025 | seekingalpha.comCapital Research Global Investors Buys 912,439 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO)Capital Research Global Investors grew its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 34.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,526,747 shares of the company's stock after purchasingApril 23, 2025 | marketbeat.comBarclays PLC Sells 97,498 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO)Barclays PLC lessened its position in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 17.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 447,510 shares of the company's stock after selling 97,498 shApril 23, 2025 | marketbeat.comBridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 pm ETApril 22, 2025 | globenewswire.comGabelli Funds LLC Takes Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Gabelli Funds LLC acquired a new position in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 73,500 shares of the company's stock, valued at approximately $2,017,000. A nApril 21, 2025 | marketbeat.comInvesco Ltd. Sells 437,330 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO)Invesco Ltd. lowered its position in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 32.9% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 893,127 shares of the company's stock after selling 437,330 shares during the period. Invesco Ltd. owned 0.47%April 21, 2025 | marketbeat.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Sold by Franklin Resources Inc.Franklin Resources Inc. lessened its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 99.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 8,598 shares of the company's stock after selling 2,296,302 shares during the quarteApril 21, 2025 | marketbeat.comLeerink Partnrs Has Positive Outlook for BBIO Q1 EarningsBridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) - Investment analysts at Leerink Partnrs upped their Q1 2025 earnings per share (EPS) estimates for shares of BridgeBio Pharma in a report released on Wednesday, April 16th. Leerink Partnrs analyst M. Foroohar now forecasts that the company willApril 20, 2025 | marketbeat.comHC Wainwright Has Pessimistic Outlook of BBIO Q1 EarningsBridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) - Investment analysts at HC Wainwright cut their Q1 2025 earnings per share estimates for BridgeBio Pharma in a research note issued on Tuesday, April 15th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($1.01) perApril 19, 2025 | marketbeat.comInsider Selling: BridgeBio Pharma, Inc. (NASDAQ:BBIO) Director Sells 10,000 Shares of StockBridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) Director Andrea Ellis sold 10,000 shares of the stock in a transaction dated Monday, April 14th. The stock was sold at an average price of $35.00, for a total transaction of $350,000.00. Following the transaction, the director now owns 12,000 shares in the company, valued at approximately $420,000. The trade was a 45.45 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.April 18, 2025 | marketbeat.comQ2 Earnings Estimate for BBIO Issued By HC WainwrightBridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) - Equities research analysts at HC Wainwright issued their Q2 2026 earnings per share estimates for BridgeBio Pharma in a research report issued to clients and investors on Tuesday, April 15th. HC Wainwright analyst R. Selvaraju expects that theApril 18, 2025 | marketbeat.comBridgeBio Pharma (NASDAQ:BBIO) Stock Price Expected to Rise, HC Wainwright Analyst SaysHC Wainwright boosted their price objective on shares of BridgeBio Pharma from $49.00 to $53.00 and gave the company a "buy" rating in a research report on Tuesday.April 17, 2025 | marketbeat.comAffinity Asset Advisors LLC Cuts Stock Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Affinity Asset Advisors LLC decreased its holdings in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 33.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 200,000 sharApril 17, 2025 | marketbeat.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Director Sells $350,000.00 in StockApril 17, 2025 | insidertrades.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Consensus Recommendation of "Moderate Buy" by BrokeragesShares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) have earned a consensus rating of "Moderate Buy" from the twelve research firms that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and eleven have given a bApril 17, 2025 | marketbeat.com Get BridgeBio Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for BBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address BBIO Media Mentions By Week BBIO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BBIO News Sentiment▼0.930.69▲Average Medical News Sentiment BBIO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BBIO Articles This Week▼289▲BBIO Articles Average Week Get BridgeBio Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for BBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Beigene News BioNTech News Summit Therapeutics News Teva Pharmaceutical Industries News Intra-Cellular Therapies News Genmab A/S News Dr. Reddy's Laboratories News Moderna News Ascendis Pharma A/S News Viatris News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BBIO) was last updated on 5/6/2025 by MarketBeat.com Staff From Our Partners3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump Orders 'National Digital Asset Stockpile'Trump's tariffs on China have caused a ripple effect across global markets. But in crypto? They've lit a fu...Crypto 101 Media | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredAll Signs Point To Collapse - 401(k)s/IRAs /Are DoomedRetiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road AheadAmerican Hartford Gold | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredREVEALED: Elon’s Secret Master Plan “AGENDA X”REVEALED: Elon's Secret Master Plan "AGENDA X" For almost 30 years, Elon worked on his master plan in secre...Brownstone Research | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BridgeBio Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BridgeBio Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BBIO Stock Free BBIO Stock Alerts